Parameter | Days after therapy | Control (P control vs. PRRT) | PRRT (P PRRT vs. PRRT + lysine) | PRRT + lysine (P control vs. PRRT + lysine) |
177Lu uptake (MBq/kidney) | 4 | — | 3.8 ± 0.3* | 2.0 ± 0.1 |
BW, % vs. day 0 | 90 | 134 ± 3* | 111 ± 6† | 127 ± 5‡ |
140 | 143 ± 4* | 113 ± 11† | 138 ± 6, NS | |
Protein in urine (mg/24 h) | 100 | 11 ± 2* | 62 ± 9* | 22 ± 8* |
Urea in serum (mmol/L) | 90 | 5.8 ± 0.2* | 10.5 ± 2.2‡ | 7.2 ± 1.0† |
140 | 5.3 ± 0.5* | 32.6 ± 9.4* | 7.3 ± 0.6* | |
Creatinine in serum (μmol/L) | 90 | 21 ± 2* | 60 ± 5* | 37 ± 3* |
140 | 24 ± 1* | 108 ± 20* | 35 ± 4* | |
Grading histologic renal damage | 140 | 0.4 ± 0.6* | 4 ± 0* | 1.3 ± 0.5‡ |
99mTc-DMSA (%IA/kidney) | 90 | 13.7 ± 1.4* | 6.4 ± 2.4* | 12.5 ± 1.2, NS |
140 | 18.1 ± 1.9* | 5.6 ± 3.2* | 14.3 ± 1.1† | |
99mTc-MAG3 (%IA/kidney, 2–6 min) | 100–120 | 13.1 ± 2.6* | 4.3 ± 1.5* | 8.5 ± 1.6* |
99mTc-MAG3 (%IA/cm3 cortex, 2–6 min) | 100–120 | 6.9 ± 1.9* | 2.6 ± 1.3‡ | 3.8 ± 1.0* |
111In-DTPA (%IA/kidney, 2–4 min) | 100–120 | 4.7 ± 1.0† | 2.1 ± 1.4, NS | 4.4 ± 0.6, NS |
↵* P < 0.0001.
↵† P < 0.001.
↵‡ P < 0.05.
NS = not significant.
Quantification of retained renal radioactivity was expressed as total MBq/kidney for 177Lu and %IA/kidney for 99mTc-DMSA. Peak activity was expressed as %IA/kidney for 111In-DTPA and 99mTc-MAG3 or as %IA/cm3 cortex for 99mTc-MAG3. BW of rats was expressed as percentage of BW at day 0. Protein loss in urine was expressed in mg/24-h urine. Serum urea and creatinine content was expressed in mmol/L or μmol/L. Histologic grading of renal damage was expressed on a scale of 0–4.